BACKGROUND: The oral formulation of vinorelbine together with capecitabine allows for an all-oral combination chemotherapy which promises to raise quality of life of patients with advanced breast cancer. PATIENTS AND METHODS: Patients with HER2-negative, locally advanced, inoperable or metastatic breast cancer were included in this prospective observational trial (treatment schedule: capecitabine 500 mg/m2 twice daily, days 1-14; vinorelbine 60 mg/m2, days 1+8; repeated in 3-week cycles). RESULTS: All 32 patients (median age 50 years) were evaluable for toxicity, and 30 patients for response. Twentyfour patients received therapy as first-line treatment, and 8 patients as beyond first-line treatment. Median time to progression was 8 months, and median overall survival was 32 months. Complete response was observed in 1 patient (3%), partial response in 10 patients (33%), and disease stabilization for more than 6 months (SD > 6) in 10 patients (33%). This results in an overall response rate (ORR) of 37% and a clinical benefit rate (ORR + SD > 6) of 70%. The only grade 3/4 toxicities were neutropenia (19%) and hand-foot syndrome (9%). CONCLUSIONS: The all-oral combination of capecitabine/vinorelbine at this schedule appears to be an effective, well-tolerated regimen for treatment of advanced breast cancer, and offers a promising alternative to single-agent capecitabine and vinorelbine as well as intravenous polychemotherapy.
BACKGROUND: The oral formulation of vinorelbine together with capecitabine allows for an all-oral combination chemotherapy which promises to raise quality of life of patients with advanced breast cancer. PATIENTS AND METHODS: Patients with HER2-negative, locally advanced, inoperable or metastatic breast cancer were included in this prospective observational trial (treatment schedule: capecitabine 500 mg/m2 twice daily, days 1-14; vinorelbine 60 mg/m2, days 1+8; repeated in 3-week cycles). RESULTS: All 32 patients (median age 50 years) were evaluable for toxicity, and 30 patients for response. Twentyfour patients received therapy as first-line treatment, and 8 patients as beyond first-line treatment. Median time to progression was 8 months, and median overall survival was 32 months. Complete response was observed in 1 patient (3%), partial response in 10 patients (33%), and disease stabilization for more than 6 months (SD > 6) in 10 patients (33%). This results in an overall response rate (ORR) of 37% and a clinical benefit rate (ORR + SD > 6) of 70%. The only grade 3/4 toxicities were neutropenia (19%) and hand-foot syndrome (9%). CONCLUSIONS: The all-oral combination of capecitabine/vinorelbine at this schedule appears to be an effective, well-tolerated regimen for treatment of advanced breast cancer, and offers a promising alternative to single-agent capecitabine and vinorelbine as well as intravenous polychemotherapy.
Authors: F Nolè; C Catania; G Sanna; K Imadalou; E Munzone; L Adamoli; B Longerey; G Blanchot; A Goldhirsch Journal: Ann Oncol Date: 2005-11-22 Impact factor: 32.976
Authors: M Terenziani; R Demicheli; C Brambilla; L Ferrari; A Moliterni; M Zambetti; A Caraceni; C Martini; G Bonadonna Journal: Breast Cancer Res Treat Date: 1996 Impact factor: 4.872
Authors: J A Oshaughnessy; J Blum; V Moiseyenko; S E Jones; D Miles; D Bell; R Rosso; L Mauriac; B Osterwalder; H U Burger; S Laws Journal: Ann Oncol Date: 2001-09 Impact factor: 32.976
Authors: V Lorusso; M Spada; M Giampaglia; A Misino; R Calabrese; A Latorre; G Monticelli; M Guida; D Sambiasi; G Colucci Journal: Ann Oncol Date: 2006-06 Impact factor: 32.976
Authors: Franco Nolè; D Crivellari; R Mattioli; G Pinotti; P Foa; E Verri; R Fougeray; M Brandely; A Goldhirsch Journal: Cancer Chemother Pharmacol Date: 2009-01-31 Impact factor: 3.333
Authors: Laura G Estévez; Norberto Batista; Pedro Sánchez-Rovira; Amalia Velasco; Mariano Provencio; Ana León; Manuel Dómine; Josefina Cruz; Milva Rodríguez Journal: Clin Breast Cancer Date: 2008-04 Impact factor: 3.225
Authors: G Freyer; T Delozier; M Lichinister; D Gedouin; P Bougnoux; P His; K Imadalou; V Trillet-Lenoir Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Sarah Schott; Andreas Schneeweiss; Judith Reinhardt; Thomas Bruckner; Christoph Domschke; Christof Sohn; Michael H Eichbaum Journal: BMC Cancer Date: 2011-04-12 Impact factor: 4.430